Novel Nomogram Predicts Survival Outcomes for Advanced NSCLC Patients Receiving Immunotherapy Beyond Progression

A new predictive model could help oncologists make more informed decisions about continuing immune checkpoint inhibitor (ICI) therapy beyond disease progression in advanced non-small cell lung cancer (search)Search disease (NSCLC (search)Search disease) patients, according to research published in Frontiers in Immunology.

The retrospective study, conducted at Nanjing Jinling Hospital (search)Search term, analyzed 153 lung cancer (search)Search disease patients who received ICI therapy beyond progression between January 2019 and February 2024. Researchers developed and validated a clinicopathologic nomogram incorporating five independent prognostic factors to predict 6-, 12-, and 24-month overall survival (OS) and progression-free survival (PFS).

Addressing Treatment Beyond Progression Uncertainty

The decision to continue ICI therapy after disease progression remains contentious in clinical practice. While some studies have reported significant survival benefits from treatment beyond progression (TBP), others have failed to confirm these advantages. Current NCCN guidelines stratify post-progression management by driver mutations, progression pattern, and PD-L1 (search)Search target status, but clinical utility remains limited by tumor heterogeneity.

"The clinical benefits of treatment beyond progression with ICIs (search)Search drug are still debated," the researchers noted. "A dynamic predictive model capable of stratifying patients by their likelihood of benefit from extended ICIs exposure is thus urgently needed to optimize pharmacological decision-making."

Five-Factor Predictive Model

Using least absolute shrinkage and selection operator (LASSO) regression with 10-fold cross-validation, researchers identified five key prognostic factors for OS: immunological combination regimens, ECOG performance status, efficacy assessment, lymph node metastasis, and liver metastasis. For PFS prediction, liver metastasis and efficacy assessment emerged as the primary prognosticators.

The nomogram demonstrated robust predictive performance with a C-index of 0.700 (95% CI: 0.636-0.772) for OS and 0.599 (95% CI: 0.535-0.662) for PFS. Time-dependent receiver operating characteristic curves showed area under the curve values of 0.786, 0.777, and 0.705 for OS at 6, 12, and 24 months, respectively.

Metastatic Site Impact on Outcomes

The study revealed striking differences in how metastatic sites influence treatment outcomes. Lymph node metastasis emerged as a protective factor (HR = 0.538, 95% CI: 0.291-0.995, p=0.048), potentially due to enriched CD4+/CD8+ memory effector T cells in metastatic lymph nodes that may enhance systemic antitumor responses.

In contrast, liver metastasis correlated with markedly worse outcomes (HR = 2.925, 95% CI: 1.360-6.290, p=0.006). This finding aligns with established mechanisms of hepatic immune tolerance, where the immunosuppressive tumor microenvironment arises from N1-acetylspermidine efflux-dependent signaling that drives macrophage polarization and regulatory T-cell recruitment.

"Patients with liver metastases exhibited the shortest median survival (3 months) compared to those with bone or central nervous system involvement," the researchers reported.

Clinical Risk Stratification

Using optimal cutoff values (OS: 129.02; PFS: 64.38), the model effectively stratified patients into distinct risk cohorts. Kaplan-Meier survival curves revealed significant disparities between groups, with the low-risk cohort achieving superior median OS (20.4 months vs. 6.7 months, p < 0.0001) and PFS (21.6 months vs. 10.3 months, p = 0.003).

Decision curve analysis confirmed significant net clinical benefit for OS prediction at 6-24 months, supporting the model's integration into TBP decisions. The visual nomogram output enhances clinician-patient communication by facilitating transparent discussions of prognosis and treatment expectations.

Treatment Regimen Considerations

The study found that initial ICI monotherapy may optimize TBP patient selection, with sequential integration of chemotherapy or antiangiogenic regimens offering additional clinical gains. While immunotherapy monotherapy demonstrates substantial efficacy in NSCLC (search)Search disease patients with high PD-L1 (search)Search target expression, even among PD-L1-high patients, 29.8% exhibit suboptimal responses to monotherapy.

Chemoimmunotherapy synergistically enhances antitumor activity through immunogenic cell death induction and immune escape pathway disruption, while anti-angiogenic agents remodel the tumor microenvironment by suppressing immunosuppressive cells and promoting T-cell infiltration via vascular normalization.

Clinical Accessibility and Implementation

Unlike genomics-driven models that require complex gene sequencing or specialized bioinformatics platforms, this nomogram relies on routinely available clinical parameters, reducing per-assessment costs and enabling real-time risk stratification in resource-limited settings.

High-risk patients (score > 129.02) may benefit from prioritized enrollment in clinical trials evaluating bispecific antibodies or novel immune combinations, while low-risk patients (score ≤ 129.02) can maintain standard-of-care regimens to avoid overtreatment toxicity.

Study Limitations and Future Directions

The researchers acknowledged several limitations, including insufficient coverage of routine biomarker testing and the inability to conduct in-depth histology-stratified subgroup modeling due to sample size constraints. The heterogeneity within PD-L1 (search)Search target-negative populations encompassing distinct resistance mechanisms remains inadequately characterized.

Future research priorities include initiating multicenter prospective cohort studies to validate racial and regional generalizability, enlarging the sample size for high-risk subgroups with liver metastasis, and establishing standardized platforms for monitoring dynamic biomarkers such as circulating tumor DNA clearance rate and tumor mutational burden dynamics.

The study provides a practical tool for precision oncology, enabling risk stratification and personalized therapeutic decision-making by identifying patients most likely to derive clinical benefit from treatment beyond progression in advanced NSCLC (search)Search disease.